Neoadjuvant--also called preoperative or primary--systemic therapy for breast cancer may result in local tumor regression or even in a complete tumor response and may lead to a more limited extent of surgery--from radical mastectomy to some type of breast-conserving surgery--without risking patient survival. For these reasons, interest in the use of neoadjuvant therapy has been increasing.
To investigate how the timing of systemic therapy affects breast cancer outcomes, John P.A. Ioannidis, M.D., of the University of Ioannina School of Medicine in Greece, and colleagues performed a meta-analysis of nine randomized trials that had included nearly 4,000 breast cancer patients. The patients had been treated with systemic therapy either before or after surgery and/or radiation therapy.
There was no difference between neoadjuvant and adjuvant systemic therapy in terms of death, disease progression, or distant disease recurrence. However, neoadjuvant therapy was associated with a 22% increased risk of loco-regional disease recurrence compared with adjuvant therapy. This risk was higher (53%) when radiation therapy was used without surgery.
"[T]his meta-analysis demonstrates the equivalence of neoadjuvant and adjuvant treatments for breast cancer in terms of survival, disease progression, and distant recurrence and shows that an increased risk of loco-regional disease recurrence is associated with neoadjuvant treatment, especially when primary systemic treatment is not accompanied by any surgical interve
Contact: Sarah L. Zielinski
Journal of the National Cancer Institute